The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis
Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 2020-12, Vol.888, p.173487-173487, Article 173487 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 173487 |
|---|---|
| container_issue | |
| container_start_page | 173487 |
| container_title | European journal of pharmacology |
| container_volume | 888 |
| creator | Habibzadeh, Parham Mofatteh, Mohammad Ghavami, Saeid Roozbeh, Jamshid |
| description | Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials. |
| doi_str_mv | 10.1016/j.ejphar.2020.173487 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7428435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299920305793</els_id><sourcerecordid>2435191491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-8f41f83a2959af470f9eb3a01c6ecba419481c1a8811f3700001159f758f878a3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS1ERYfCP0DISzYZfB1nYrNAqoZXpUrdtGwtj3NNHDLxYCcjDb8eRymFbrq6kn3OuY-PkDfA1sBg875bY3doTVxzxvNTXQpZPyMrkLUqWA38OVkxBqLgSqlz8jKljjFWKV69IOcll6zi1WZFwm2L9BBGHEZveorOoR39EQdMiQZHjcXR_A692fsGqR_oOOsjHmdDGBbJNCL96ZsBT1nRTXEudHvz_epTAeoDvaTtKbdoMfn0ipw50yd8fV8vyN2Xz7fbb8X1zder7eV1YcWmHAvpBDhZGq4qZZyomVO4Kw0Du0G7MwKUkGDBSAngyjpvxgAq5epKOllLU16Qj0vuYdrtsbF53Gh6fYh-b-JJB-P145_Bt_pHOOpacCnKKge8uw-I4deEadR7nyz2vRkwTEnzLAIFQkGWikVqY0gpontoA0zPrHSnF1Z6ZqUXVtn29v8RH0x_4fzbAfOhjh6jTtbjYLHxMVPSTfBPd_gDZMKoLQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435191491</pqid></control><display><type>article</type><title>The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Habibzadeh, Parham ; Mofatteh, Mohammad ; Ghavami, Saeid ; Roozbeh, Jamshid</creator><creatorcontrib>Habibzadeh, Parham ; Mofatteh, Mohammad ; Ghavami, Saeid ; Roozbeh, Jamshid</creatorcontrib><description>Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2020.173487</identifier><identifier>PMID: 32805256</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acetazolamide ; Acetazolamide - therapeutic use ; Acute kidney injury ; Acute Kidney Injury - etiology ; Acute Kidney Injury - prevention & control ; Angiotensin-Converting Enzyme 2 ; Carbonic Anhydrase Inhibitors - therapeutic use ; Carbonic anhydrases ; Coronavirus Infections - complications ; COVID-19 ; Full Length ; Humans ; Kidney Tubules, Proximal - cytology ; Kidney Tubules, Proximal - virology ; Pandemics ; Peptidyl-Dipeptidase A - metabolism ; Pneumonia, Viral - complications ; SARS-CoV-2 ; Treatment Outcome</subject><ispartof>European journal of pharmacology, 2020-12, Vol.888, p.173487-173487, Article 173487</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-8f41f83a2959af470f9eb3a01c6ecba419481c1a8811f3700001159f758f878a3</citedby><cites>FETCH-LOGICAL-c463t-8f41f83a2959af470f9eb3a01c6ecba419481c1a8811f3700001159f758f878a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2020.173487$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32805256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Habibzadeh, Parham</creatorcontrib><creatorcontrib>Mofatteh, Mohammad</creatorcontrib><creatorcontrib>Ghavami, Saeid</creatorcontrib><creatorcontrib>Roozbeh, Jamshid</creatorcontrib><title>The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials.</description><subject>Acetazolamide</subject><subject>Acetazolamide - therapeutic use</subject><subject>Acute kidney injury</subject><subject>Acute Kidney Injury - etiology</subject><subject>Acute Kidney Injury - prevention & control</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>Carbonic anhydrases</subject><subject>Coronavirus Infections - complications</subject><subject>COVID-19</subject><subject>Full Length</subject><subject>Humans</subject><subject>Kidney Tubules, Proximal - cytology</subject><subject>Kidney Tubules, Proximal - virology</subject><subject>Pandemics</subject><subject>Peptidyl-Dipeptidase A - metabolism</subject><subject>Pneumonia, Viral - complications</subject><subject>SARS-CoV-2</subject><subject>Treatment Outcome</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhS1ERYfCP0DISzYZfB1nYrNAqoZXpUrdtGwtj3NNHDLxYCcjDb8eRymFbrq6kn3OuY-PkDfA1sBg875bY3doTVxzxvNTXQpZPyMrkLUqWA38OVkxBqLgSqlz8jKljjFWKV69IOcll6zi1WZFwm2L9BBGHEZveorOoR39EQdMiQZHjcXR_A692fsGqR_oOOsjHmdDGBbJNCL96ZsBT1nRTXEudHvz_epTAeoDvaTtKbdoMfn0ipw50yd8fV8vyN2Xz7fbb8X1zder7eV1YcWmHAvpBDhZGq4qZZyomVO4Kw0Du0G7MwKUkGDBSAngyjpvxgAq5epKOllLU16Qj0vuYdrtsbF53Gh6fYh-b-JJB-P145_Bt_pHOOpacCnKKge8uw-I4deEadR7nyz2vRkwTEnzLAIFQkGWikVqY0gpontoA0zPrHSnF1Z6ZqUXVtn29v8RH0x_4fzbAfOhjh6jTtbjYLHxMVPSTfBPd_gDZMKoLQ</recordid><startdate>20201205</startdate><enddate>20201205</enddate><creator>Habibzadeh, Parham</creator><creator>Mofatteh, Mohammad</creator><creator>Ghavami, Saeid</creator><creator>Roozbeh, Jamshid</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201205</creationdate><title>The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis</title><author>Habibzadeh, Parham ; Mofatteh, Mohammad ; Ghavami, Saeid ; Roozbeh, Jamshid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-8f41f83a2959af470f9eb3a01c6ecba419481c1a8811f3700001159f758f878a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetazolamide</topic><topic>Acetazolamide - therapeutic use</topic><topic>Acute kidney injury</topic><topic>Acute Kidney Injury - etiology</topic><topic>Acute Kidney Injury - prevention & control</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>Carbonic anhydrases</topic><topic>Coronavirus Infections - complications</topic><topic>COVID-19</topic><topic>Full Length</topic><topic>Humans</topic><topic>Kidney Tubules, Proximal - cytology</topic><topic>Kidney Tubules, Proximal - virology</topic><topic>Pandemics</topic><topic>Peptidyl-Dipeptidase A - metabolism</topic><topic>Pneumonia, Viral - complications</topic><topic>SARS-CoV-2</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Habibzadeh, Parham</creatorcontrib><creatorcontrib>Mofatteh, Mohammad</creatorcontrib><creatorcontrib>Ghavami, Saeid</creatorcontrib><creatorcontrib>Roozbeh, Jamshid</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Habibzadeh, Parham</au><au>Mofatteh, Mohammad</au><au>Ghavami, Saeid</au><au>Roozbeh, Jamshid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2020-12-05</date><risdate>2020</risdate><volume>888</volume><spage>173487</spage><epage>173487</epage><pages>173487-173487</pages><artnum>173487</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32805256</pmid><doi>10.1016/j.ejphar.2020.173487</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 2020-12, Vol.888, p.173487-173487, Article 173487 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7428435 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Acetazolamide Acetazolamide - therapeutic use Acute kidney injury Acute Kidney Injury - etiology Acute Kidney Injury - prevention & control Angiotensin-Converting Enzyme 2 Carbonic Anhydrase Inhibitors - therapeutic use Carbonic anhydrases Coronavirus Infections - complications COVID-19 Full Length Humans Kidney Tubules, Proximal - cytology Kidney Tubules, Proximal - virology Pandemics Peptidyl-Dipeptidase A - metabolism Pneumonia, Viral - complications SARS-CoV-2 Treatment Outcome |
| title | The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A28%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20effectiveness%20of%20acetazolamide%20in%20the%20prevention%20of%20acute%20kidney%20injury%20in%20COVID-19:%20A%20hypothesis&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Habibzadeh,%20Parham&rft.date=2020-12-05&rft.volume=888&rft.spage=173487&rft.epage=173487&rft.pages=173487-173487&rft.artnum=173487&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2020.173487&rft_dat=%3Cproquest_pubme%3E2435191491%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435191491&rft_id=info:pmid/32805256&rft_els_id=S0014299920305793&rfr_iscdi=true |